The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
A Multifunctional Envelope-type Nanodevice for Use in Nanomedicine: Concept and Applications
Abstract
In the 21st century, drug development has shifted toward larger molecules such as proteins and nucleic acids, which require the use of new chemical strategies. In this process, the drug delivery system plays a central role and intracellular targeting using nanotechnology has become a key technology for the development of successful new medicines. We have developed a new delivery system, a multifunctional envelope-type nanodevice (MEND) based on "Programmed Packaging." In this new concept of packaging, multifunctional nanodevices are integrated into a nanocarrier system according to a program designed to overcome all barriers during the course of biodistribution and intracellular trafficking. In this Account, we introduce our method for delivering nucleic acids or proteins to intracellular sites of action such as the cytosol, nucleus, and mitochondria and for targeting selective tissues in vivo via systemic administration of the nanodevices. First, we introduce an octaarginine-modified MEND (R8-MEND) as an efficient intracellular delivery system, designed especially for vaccinations and transgene expression. Many types of cells can internalize the R8-MEND, mainly by inducing macropinocytosis, and the MEND escapes from macropinosomes via membrane fusion, which leads to efficient antigen presentation via the major histocompatibility complex I pathway in antigen-presenting cells. In addition, the transfection activities of the R8-MEND in dividing cells, such as HeLa or A549 cells…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, a tetra-lamellar MEND (T-MEND) was developed that targeted the cellular nucleus and mitochondria, and a PEG-peptide-DOPE-conjugated MEND (PPD-MEND) was developed that targeted bladder cancer cells (Nakamura et al., 2012).”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Nakamura et al., 2012
Citations
Cites
Mitochondrial DNA mutations and human disease
Tuppen, H. A. L., Blakely, E. L., Turnbull, D. M., & Taylor, R. W. (2010) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2009.09.005 · Cited by 676
Li, W. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.041 · Cited by 588
Dynein- and microtubule-mediated translocation of adenovirus serotype 5 occurs after endosomal lysis
Leopold, P. L., Kreitzer, G., Miyazawa, N., Rempel, S., Pfister, K. K., Rodriguez-Boulan, E., & Crystal, R. G. (2000) · Human Gene Therapy · doi:10.1089/10430340050016238 · Cited by 254
Research works printed but not linked: 37
- Kogure K., 2008, Adv. Drug Delivery Rev., 60, 559, 10.1016/j.addr.2007.10.007 · DOI · Paper page
- Hatakeyama H., 2011, Adv. Drug Delivery Rev., 63, 152, 10.1016/j.addr.2010.09.001 · DOI · Paper page
- Futaki S., 2001, Bioconjugate Chem., 12, 1005, 10.1021/bc015508l · DOI · Paper page
- Khalil I. A., 2006, J. Biol. Chem., 281, 3544, 10.1074/jbc.M503202200 · DOI · Paper page
- Khalil I. A., 2006, Pharmacol. Rev., 58, 32, 10.1124/pr.58.1.8 · DOI · Paper page
- El-Sayed A., 2008, J. Biol. Chem., 283, 23450, 10.1074/jbc.M709387200 · DOI · Paper page
- Nakamura T., 2008, Mol. Ther., 16, 1507, 10.1038/mt.2008.122 · DOI
- Homhuan A., 2007, J. Controlled Release, 120, 60, 10.1016/j.jconrel.2007.03.017 · DOI
- Joraku A., 2009, BJU Int., 103, 686, 10.1111/j.1464-410X.2008.08235.x · doi:10.1111/j.1464-410x.2008.08235.x
- Kogure K., 2004, J. Controlled Release, 98, 317, 10.1016/j.jconrel.2004.04.024 · DOI · Paper page
- Khalil I. A., 2007, Gene Ther., 14, 682, 10.1038/sj.gt.3302910 · DOI · Paper page
- Nakamura Y., 2007, J. Controlled Release, 119, 360, 10.1016/j.jconrel.2007.03.010 · DOI · Paper page
- Subramanian A., 1999, Nat. Biotechnol., 17, 873, 10.1038/12860 · DOI · Paper page
- Akita H., 2010, Mol. Ther., 18, 955, 10.1038/mt.2010.33 · DOI
- Akita H., 2009, Biomaterials, 30, 2940, 10.1016/j.biomaterials.2009.02.009 · DOI
- Shaheen, S. M.; Akita, H.; Nakamura, T.; Takayama, S.; Futaki, S.; Yamashita, A.; Katoono, R.; Yui, N.; Harashima, H.KALA-modified multi-layered nanoparticles as gene carriers for MHC class-I mediated antigen presentation for a DNA vaccine.Biomaterials 2012, in press. · DOI
- Hama S., 2007, Nucleic Acids Res., 35, 1533, 10.1093/nar/gkl1165 · DOI
- Hama S., 2006, Mol. Ther., 13, 786, 10.1016/j.ymthe.2005.10.007 · DOI · Paper page
- Shaheen S. M., 2011, Nucleic Acids Res., 39, e48, 10.1093/nar/gkq1327 · DOI
- Yamashita A., 2008, J. Controlled Release, 131, 137, 10.1016/j.jconrel.2008.07.011 · doi:10.1016/j.jconrel.2008.07.011
- Holt I. J., 1988, Nature, 331, 717, 10.1038/331717a0 · DOI · Paper page
- Zhang E., 2011, Drug Discovery Today, 16, 140, 10.1016/j.drudis.2010.12.006 · DOI
- Flierl A., 2003, Mol. Ther., 7, 550, 10.1016/S1525-0016(03)00037-6 · DOI
- D’Souza G. G., 2005, Mitochondrion, 5, 352, 10.1016/j.mito.2005.07.001 · DOI
- Yamada Y., 2008, Biochim. Biophys. Acta, 1778, 423, 10.1016/j.bbamem.2007.11.002 · DOI · Paper page
- Yasuzaki Y., 2010, Biochem. Biophys. Res. Commun., 397, 181, 10.1016/j.bbrc.2010.05.070 · DOI
- Yamada Y., 2011, Mol. Ther., 19, 1449, 10.1038/mt.2011.99 · DOI
- Yamada, Y.; Harashima, H.Delivery of bioactive molecules to the mitochondrial genome using a membrane-fusing, liposome-based carrier, DF-MITO-Porter.Biomaterials 2012, in press. · DOI
- Matsumura Y., 1986, Cancer Res., 46, 6387
- Klibanov A. L., 1990, FEBS Lett., 268, 235, 10.1016/0014-5793(90)81016-H · DOI · Paper page
- Mishra S., 2004, Eur. J. Cell Biol., 83, 97, 10.1078/0171-9335-00363 · DOI · Paper page
- Hatakeyama H., 2007, Gene Ther., 14, 68, 10.1038/sj.gt.3302843 · DOI · Paper page
- Hatakeyama H., 2011, Biomaterials, 32, 4306, 10.1016/j.biomaterials.2011.02.045 · DOI · Paper page
- Hafez I. M., 2001, Adv. Drug Delivery Rev., 47, 139, 10.1016/S0169-409X(01)00103-X · DOI · Paper page
- Hatakeyama H., 2009, J. Controlled Release, 139, 127, 10.1016/j.jconrel.2009.06.008 · DOI · Paper page
- Sakurai Y., 2009, Biol. Pharm. Bull., 32, 928, 10.1248/bpb.32.928 · DOI
- Sakurai Y., 2011, Biomaterials, 32, 5733, 10.1016/j.biomaterials.2011.04.047 · DOI
Cited by
Delivering CRISPR: a review of the challenges and approaches
Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1474964 · Cited by 1,185
Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review
Kanamala, M., Wilson, W. R., Yang, M., Palmer, B. D., & Wu, Z. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.01.061 · Cited by 1,004
Wang, H.-X., Li, M., Lee, C. M., Chakraborty, S., Kim, H.-W., Bao, G., & Leong, K. W. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00799 · Cited by 560
Hatakeyama, H., Akita, H., & Harashima, H. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00059 · Cited by 495
Self-citationAriga, K., Yamauchi, Y., Mori, T., & Hill, J. P. (2013) · Advanced Materials · doi:10.1002/adma.201302283 · Cited by 493
Nanopreparations for organelle-specific delivery in cancer
Biswas, S., & Torchilin, V. P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.004 · Cited by 292
CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases
Sharma, G., Sharma, A. R., Bhattacharya, M., Lee, S.-S., & Chakraborty, C. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.028 · Cited by 283
Du, J.-Z., Li, H.-J., & Wang, J. (2018) · Accounts of Chemical Research · doi:10.1021/acs.accounts.8b00195 · Cited by 276
Metadata
- Authors
- Nakamura, T., Akita, H., Yamada, Y., Hatakeyama, H., & Harashima, H.
- Affiliations
- Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Sapporo City, Hokkaido 060-0812, Japan
- Venue
- Accounts of Chemical Research
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-02-10
- Volume
- 45
- Issue
- 7
- Pages
- 1113-1121
- ISSN
- 0001-4842
- 1520-4898
- Cited by
- 88
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.